Novanta Inc. designs, manufactures, markets and sells precision motion, vision and photonics components and subsystems to original equipment manufacturers in the medical and industrial markets worldwide. The company is headquartered in Bedford, Massachusetts.
| Revenue (TTM) | $1.03B |
| Gross Profit (TTM) | $458.68M |
| EBITDA | $180.95M |
| Operating Margin | 11.50% |
| Return on Equity | 5.11% |
| Return on Assets | 4.09% |
| Revenue/Share (TTM) | $26.45 |
| Book Value | $42.74 |
| Price-to-Book | 3.90 |
| Price-to-Sales (TTM) | 6.12 |
| EV/Revenue | 5.7 |
| EV/EBITDA | 32.31 |
| Quarterly Earnings Growth (YoY) | 150.00% |
| Quarterly Revenue Growth (YoY) | 10.30% |
| Shares Outstanding | $37.82M |
| Float | $37.54M |
| % Insiders | 0.71% |
| % Institutions | 123.58% |
Volatility is currently expanding
If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novanta NASDAQ: NOVT reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition.
Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) July 3, June 27, 2026 2025 GAAP Revenue $ 265.8 $ 241.0 Operating Income $ 18.1 $ 14.9 Net Income $ 12.5 $ 4.5 Diluted EPS $ 0.30 $ 0.12.
Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and.
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the con.
Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NOVT and any ticker you trade — then tracks every position and per-strategy win rate.
